Almac Sciences Achieves Thought Leadership Milestone
October 14, 2020
Professor Tom Moody Exceeds 100 Technical Publications Since Tenure at Almac
Craigavon, Northern Ireland – 14 October 2020 – Almac Sciences, a member of the Almac Group, is pleased to congratulate Professor Tom Moody, VP of Technology Development and Commercialisation, for achieving the impressive milestone of over 100 peer reviewed publications since beginning his tenure with the organisation.
Professor Moody is a seasoned technical expert in chiral chemistry and biocatalysis with more than 18 years of extensive academic and industry experience. In recent years, his publications have centred on the economic and environmental benefits of “green” chemical methods, including biocatalysis, a direct and simple way to synthesise complex achiral and chiral compounds, and most recently innovations in continuous flow chemistry.
At Almac Sciences and Arran Chemical Company, Professor Moody is responsible for driving new technology processes from conception to commercial scale-up across multi-disciplinary research including enzyme engineering, biocatalysis, flow chemistry, isotope chemistry, custom synthesis and commercial production.
He previously held the role of Head of Biocatalysis and Isotope Chemistry, where he led the development of Almac Sciences’ Biocatalysis Technology platform selectAZymeTM. He also played an integral role in the integration of Arran Chemical Company Ltd into Almac Sciences and ensured smooth transfer of manufacturing projects from Craigavon to the Arran site in Athlone, Ireland.
Professor Moody is a tenured honorary professor at Queens University Belfast in the area of Green Chemistry. In addition to his accolades in Chemistry including a Bachelor of Science (BSc) in Chemistry (First Class Hons) and a PhD in Organic Chemistry he holds a Master’s in Business with Distinction in Business Strategy.
Professor Moody commented, “At Almac Sciences, it is a fundamental value of our organisation to be innovative and share acquired technical knowledge that will advance our industry, particularly in areas that can reduce the environmental impact and cost of chemical production. I am grateful for the many opportunities I have received to share the innovative methods we’re developing with the wider industry and academic communities through publication and look forward to the continued opportunity to do so in the future.”
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.